JPRN-UMIN000006970已完成3 期
A placebo controlled phase III double blind study of ITK-1 -The efficacy and safety evaluation of ITK-1 in Temozolomide refractory Glioblastoma patients with HLA-A24 positive- - A placebo controlled phase III double blind study of ITK-1
Kurume University Cancer Vaccine Center0 个研究点目标入组 110 人开始时间: 2012年1月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Infratentorial tumor, gliomatosis cerebri, meningeal dissemination 2)Hypersensitivity to mineral oil or mannitol oleate or contrast medium for MRI 3)Severe complications 4)Active multiple cancers 5)Received ITK-1 in the m for MRI past 6)Entry to the other clinical trial within 2 months prior to entry to this study 7)Difficult to participate in this trial because of psychiatric symptoms 8)Pregnant or breast-feeding patients 9)Any other cases who are judged as being ineligible for this study by physician
研究者
相似试验
已完成
3 期
A Placebo Controlled Phase III Double Blind Study of ITK-1 in Patients with Prostate Cancer - A Clinical Evaluation of ITK-1 in Castration-Resistant, Docetaxel Refractory Prostate Cancer Patients with HLA-A24 positive <Confirmatory Study>Prostate cancerJPRN-UMIN000011308BrightPath Biotherapeutics Co., Ltd.333
进行中（未招募）
1 期
A double-blind placebo-controlled Phase III study to assess the efficacy of MAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma - MAGE3-AS15-MEL-005 (ADJ)Patients with histologically proven stage IIIB or IIIC cutaneous melanoma with macroscopic lymph node involvement suitable for surgical resection. Macroscopic lymph node involvement is defined as clinically detectable lymph node metastases confirmed by therapeutic lymphadenectomyEUCTR2008-002447-16-GRGlaxoSmithKline Biologicals1,300
进行中（未招募）
1 期
A Phase III Study to Test the Benefit of a New Kind of Anti-cancerTreatment in Patients With Melanoma, After Surgical Removal of TheirTumorEUCTR2008-002447-16-BGGlaxoSmithKline Biologicals1,300
已完成
3 期
A Phase 3 Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients with Hereditary Angioedema (HAE)HAE1000533010002426Hereditary angioedemaNL-OMON51690Ionis Pharmaceuticals, Inc.8
已完成
3 期
Phase III Double-blinded, Placebo Controlled Study of Xilonix* for Improving Survival in Metastatic Colorectal CancerMetastatic Colorectal Cancer - Cancer of the colon or the rectum that has spread10017990NL-OMON45233XBiotech Germany GmbH12